



thor medical

Norwegian Prime Minister Jonas Gahr Støre to Officially Open Thor Medical's AlphaOne Facility on October 19

7.10.2026 07:00:00 CEST | Thor Medical ASA | Non-regulatory press releases

Thor Medical, a leading supplier of high-purity isotopes to the radiopharmaceutical industry, today announced that Norwegian Prime Minister Jonas Gahr Støre will officially open the Company's AlphaOne production facility at Herøya Industrial Park on October 19, 2026.

The opening was originally scheduled for September 9 but was postponed out of respect for the occasion, as it coincided with the funeral of King Harald V.

Andrew Adamovich, Founder of AdvanCell, a leading clinical-stage radiopharmaceutical company with operations across North America and Australia, will also attend the opening and share his perspective on the rapidly growing field of targeted alpha therapy and the critical role of reliable isotope supply in bringing these therapies to patients at scale.

The opening ceremony will bring together guests from the radiopharmaceutical industry, the Norwegian industrial and life science ecosystem, politics and business. The ceremony is an invitation-only event. Members of the media wishing to attend are asked to contact Mathias Nilsen Reiervik at mathias.reiervik@thormedical.com for accreditation.

For further information, please contact:

Mathias Nilsen Reiervik
Head of Communications and Corporate Affairs
+47 988 05 724
mathias.reiervik@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is a leading supplier of high-purity isotopes to the radiopharmaceutical industry. The Company's proprietary production platform combines advanced separation technology with industrial-scale manufacturing capacity to deliver a reliable, scalable and cost-efficient supply of alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical companies from early-stage development to commercialization enabling scale-up of next-generation targeted cancer therapies.

Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally occurring thorium, Thor Medical's production process requires neither irradiation nor nuclear reactors, providing significant cost advantages while minimizing radioactive waste.

Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by powering the next generation of precision cancer treatment with high-purity isotopes.

Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit thormedical.com.

Attachments

- [Download announcement as PDF.pdf](#)